CONNECT WITH US
Funding Tracker

Funding Tracker

CureSkin posts Rs 133 Cr revenue and Rs 35 Cr loss in FY26

Entrackr logo

Published on

Add as a preferred source on Google
CureSkin posts Rs 133 Cr revenue and Rs 35 Cr loss in FY26

Skincare and dermatology startup CureSkin improved its financial performance in FY26, with higher revenue from product sales and services and lower advertising and promotional costs helping reduce its losses. 

The firm’s revenue from operations grew 27.9% to Rs 133 crore in FY26, according to its financial statements filed with the Registrar of Companies.

The Bengaluru-based company offers personalised skincare and haircare solutions through digital consultations and products recommended for individual skin and hair concerns. Its business combines product sales with services, including dermatology-led consultations.

Product sales remained its primary revenue source, accounting for about 91% of operating revenue. Revenue from products increased 17.1% to Rs 120.6 crore in FY26 from Rs 103 crore in FY25. Revenue from services, meanwhile, rose nearly ninefold to Rs 12.4 crore, albeit on a smaller base. The increase points to a larger contribution from services, although product sales continued to account for most of the business.

The firm also reported Rs 1 crore in other income, taking total revenue to Rs 134 crore in FY26, compared with Rs 108 crore a year earlier.

CureSkin’s advertising and promotional spend fell by 17.6% to Rs 61 crore in FY26 from Rs 74 crore a year earlier, reducing one of its major cost heads. The decline helped bring down overall expenditure despite higher spending on materials and other operating costs.

4% to Rs 42 crore, broadly tracking the rise in product sales. 9 crore, adding to the savings from lower promotional spending.



Source link

Disclaimer

We strive to uphold the highest ethical standards in all of our reporting and coverage. We TheMorningPulse.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It's possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.